Division of Abbott Laboratories Inc.
Latest From Abbott Vascular
Interventional cardiologists can expect important updates on transcatheter valves and drug-eluting stents during this year's late-breaking trials presented at the annual Transcatheter Cardiovascular Therapeutics meeting next week. They include updates from Edwards Lifesciences, Medtronic, Boston Scientific and Abbott.
Abbott's defunct Absorb BVS stent's efficacy is noninferior to that of the Xience metallic everolimus-eluting stent, new data presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego show. But the risk of thrombotic events was still higher with Absorb. This prompted a discussion among panelists whether bioresorbable stents should still be investigated, given the availability of newer-generation drug-eluting stents, which have shown to be safer.
Data presented at the Transcatheter Cardiovascular Therapeutics conference Sept. 23 in San Diego will support expanding the label of Abbott's MitraClip mitral valve repair device to include secondary, or functional, mitral regurgitation, a company executive tells Medtech Insight. In the COAPT trial, MitraClip reduced the two-year rate of heart-failure hospitalization and all-cause mortality in patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation.
ESC Congress 2018 Wrap-Up: Medtronic's Arctic Front; B. Braun's SeQuent Please; Biotronik's Orsiro Stent
Almost 33,000 cardiology professionals attended the 2018 European Society of Cardiology Congress last week in Munich. The meeting included 4,500 abstracts, including 17 late-breaking clinical trials, six clinical trial updates, and 20 registries. Here are some of the highlights of interest to the medtech industry.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Abbott Vascular Devices
- North America
- Parent & Subsidiaries
- Abbott Laboratories Inc.
- Senior Management
- Contact Info
Phone: (408) 845-3000
3200 Lakeside Dr.
Santa Clara, CA 95054-2807
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.